American College of Cardiology Meeting In Brief: Warner-Lambert's Accupril
Executive Summary
Warner-Lambert's Accupril: Six-month treatment with Accupril (quinapril) improves endothelial function, an early marker of coronary atherosclerosis, in patients with established coronary disease and abnormal responses to acetylcholine, according to results from the Trial on Reversing Endothelial Dysfunction (TREND), presented March 24. In 129 patients undergoing PTCA randomized to 40 mg quinapril daily or placebo, the mean percent change in acetylcholine-induced diameter of the target coronary segment at six months was a 12.1% increase for quinapril and a .8% decrease for placebo (p=.002) in patients with 10-4 m diameters...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth